Clinical trials: Immunoglobulin
Influenza, COVID-19
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
- Trial name
- NCT06020118
- Testing
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
- Where
- 8 sites in United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Duke University
MPO-ANCA Vasculitis, Microscopic Polyangiitis
CellCept in p-ANCA Vasculitis
Microscopic polyangiitis (MP) is a primary systemic vasculitis predominantly affecting small blood vessels. Following the widespread introduction of ANCA testing, the primary systemic vasculitis (SV), Wegener?s granulomatosis…
- Trial name
- NCT00405860
- Testing
- CellCept (mycophenolate mofetil)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
ATTR Amyloidosis
The Italian Transthyretin Amyloidosis Web-Network
The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and…
- Trial name
- ITA-WebNet (NCT05444920)
- Where
- 30 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
NASOPHARYNGEAL CARCINOMA
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
In this study NPC patient will receive 4 days of treatment with CD45 antibody followed by one dose of LMP1- and LMP2-CTL. From this, we can learn if treating the patient first with the CD45 antibody will also let LMP1- and…
- Trial name
- DELLA (NCT00515957)
- Testing
- genetically modified CTLs in combo with CD45 antibodies
- Sponsor
- Baylor College of Medicine
Kidney Transplant Rejection
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR).
- Trial name
- NCT07006532
- Testing
- Tocilizumab
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Graft vs Host Disease
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease
Acute graft versus host disease (GVHD) remains one of the most significant and potentially lethal complications of allogeneic bone marrow transplantation.
- Trial name
- NCT00228839
- Testing
- Infliximab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
B-cell Acute Lymphoblastic Leukemia
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Hypotheses: The Investigator hypothesizes that targeting ALL cells with 2 different modalities, ie liposomal vincristine sulfate as a microtubule inhibitor and blinatumomab as a BITE immuno-oncology therapy, will have at least…
- Trial name
- NCT04448834
- Testing
- Blinatumomab
- Where
- 3 sites in United States
- Sponsor
- Dorothy Sipkins, MD, PhD
Stiff Person Syndrome
A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome
The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).
- Trial name
- NCT07552987
- Testing
- Kedrion IVIg 10%, Human Albumin
- Volunteers
- 38 people
- Sponsor
- Kedrion S.p.A.
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
ANCA-Associated Vasculitis
Pediatric ANCA Associated-vasculitis
The incidence in pediatrics is very low (about 0.5 per million according to a French study) and therefore the data on the pathology very poor, especially on the therapeutic level.
- Trial name
- PediANCA (NCT05383573)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Poliomyelitis
Duration of IPV Priming and Antibody Decay
This is an open-label randomized phase IV clinical trial assessing immunogenicity of poliovirus vaccines.Participants will be enrolled at 6 weeks of age and followed to 18 months of age.
- Trial name
- NCT03202719
- Testing
- Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age, Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age, Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
- Where
- 2 sites in Bangladesh
- Volunteers
- 1,645 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Multiple Sclerosis
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
- Trial name
- NCT00336557
- Testing
- NAbs testing
- Where
- 49 sites in United States
- Volunteers
- 1,230 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Advanced Squamous Non-small Cell Lung Cancer
Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens…
- Trial name
- sNSCLC (NCT03808701)
- Testing
- SCT200
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Platinum-sensitive Ovarian Cancer
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer(PSOC)
- Trial name
- NCT06686030
- Testing
- AK112 low dose, Chemotherapy, Olaparib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Akeso
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally…
- Trial name
- NCT06116136
- Testing
- S095029, pembrolizumab 200 mg (KEYTRUDA ®)
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 48 people
- Sponsor
- Servier Bio-Innovation LLC
Solid Organ Transplant Recipients
TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients
Covid-19 has a very bad prognosis in solid organ transplant recipients with a 60 days-mortality exceeding 20%. For this reason, transplant patients were prioritized to receive Covid-19 vaccination since December 2020 in France.
- Trial name
- TIXCI-TRANS (NCT05234398)
- Testing
- Blood and saliva samplings
- Where
- 2 sites in France
- Sponsor
- Hospices Civils de Lyon
Amyloid, Amyloidosis
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
- Conditions
- Amyloid, Amyloidosis, AL Amyloidosis
- Trial name
- STARR (NCT04984330)
- Testing
- Selinexor, Dexamethasone
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Asthma Acute
Use of Dupilumab in Asthma in Real-world Setting
The main objective of asthma pharmacological management in adults and teenagers is to maintain long-term control of the disease, including symptom relief, the prevention of exacerbations, the improvement of pulmonary function…
- Trial name
- DUPILUMAB (NCT07637292)
- Where
- France
- Volunteers
- 35,000 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
The WINGMEN trial aims to understand how a hormone-like protein called insulin-like growth factor (IGF) helps prostate cancers grow and become aggressive.
- Trial name
- WINGMEN (NCT05110495)
- Testing
- Xentuzumab
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.